Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy

Area of Science:

• Neuroscience
• Genetics
• Biotechnology

Background:

• Age-related neurodegenerative diseases pose significant health risks and mortality.
• Current treatments for these conditions are limited and often ineffective at addressing root causes.

Purpose of the Study:

• To discuss the advantages of adeno-associated virus (AAV)-based gene therapies for neurodegenerative diseases.
• To highlight advancements in developing novel AAV capsids for enhanced therapeutic efficacy.
• To summarize clinical trial outcomes for AAV-based gene therapies in Alzheimer's disease, Parkinson's disease, and ALS.

Main Methods:

• Review of existing literature on AAV-based gene therapy safety and efficacy.
• Analysis of data from clinical trials for monogenic diseases treated with AAV.
• Summary of clinical trial results for Alzheimer's disease, Parkinson's disease, and ALS.

Main Results:

• AAV-based gene therapies have demonstrated safety in clinical trials for monogenic disorders.
• Novel capsid development is crucial for improving therapeutic outcomes in neurodegenerative conditions.
• Clinical trial data for Alzheimer's disease, Parkinson's disease, and ALS are being compiled and analyzed.

Conclusions:

• AAV-based gene therapy represents a promising therapeutic strategy for neurodegenerative diseases.
• Continued development of AAV capsids is essential for maximizing treatment effectiveness.
• Clinical trials provide valuable insights into the potential of AAV gene therapy for conditions like AD, PD, and ALS.